Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
YTH N6-methyladenosine RNA binding protein 1 (YTHDF1) is a key eukaryotic reader protein that specifically recognizes and binds to N6-methyladenosine (m6A)-modified cellular RNAs. By interacting with the translation machinery, such as eukaryotic initiation factor 3 (eIF3), YTHDF1 promotes the translation efficiency of its target mRNAs. In oncology, YTHDF1 is frequently overexpressed and acts as an oncogene across various malignancies, including colorectal, breast, and lung cancers, where it drives tumor proliferation, metastasis, and chemoresistance. Furthermore, YTHDF1 plays a critical role in shaping an immunosuppressive tumor microenvironment by suppressing dendritic cell cross-presentation and CD8+ T-cell infiltration, making it a highly attractive target for cancer immunotherapy. Emerging small-molecule inhibitors, such as SKLB-Y13 and salvianolic acid C, target the m6A-binding pocket of YTHDF1 to disrupt its interaction with methylated transcripts, thereby suppressing oncogenic translation and restoring anti-tumor immunity. However, therapeutic targeting of YTHDF1 must navigate potential safety concerns, as knockout models in mice have demonstrated cognitive and memory deficits, highlighting its physiological role in synaptic plasticity and learning.
Inhibition of YTHDF1 by binding to its m6A-binding pocket, disrupting its interaction with m6A-modified mRNAs, and thereby suppressing the translation of oncogenic target proteins.
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on YTH N6-methyladenosine RNA binding protein 1 (YTHDF1).